Use of antiretrovirals in pregnant women living with HIV in Brazil: A retrospective cohort, 2014-2019
DOI:
https://doi.org/10.33448/rsd-v14i1.47991Keywords:
Pregnant women; Antiretrovirals; Brazil.Abstract
HIV cases in Brazilian women primarily occur during their reproductive years, with increasing detection rates among pregnant women in recent years. Changes in antiretroviral therapy (ART) protocols have influenced the management of pregnant women living with HIV (PWLHIV). Objective: To evaluate the use of antiretrovirals (ARVs) and the sociodemographic profile of PWLHIV in Brazil between 2014 and 2019. Methods: A retrospective cohort study was conducted using data from the Drug Logistics Control System (SICLOM). Women aged 14 years or older with at least one ARV dispensation during pregnancy were included. Pregnant women were categorized as those with prior ART use or those initiating ART during pregnancy. Descriptive and analytical statistics were applied. Results: The study included 34,659 pregnant women: 53.3% had prior ART use, and 46.7% initiated ART during pregnancy. Most were aged 30-39 years (32.6%), non-white (46.7%), without a partner (38.5%), and had 8-11 years of education (27.7%). The mean ART duration was 174.2 days, with adverse drug reactions reported by 14.3%. ARV regimens evolved during the study period, with lopinavir + ritonavir/zidovudine + lamivudine used until 2016, tenofovir + lamivudine + efavirenz in 2017, and tenofovir + lamivudine/raltegravir from 2018 onwards. Conclusion: ART use among PWLHIV aligned with national protocols, reflecting consistent practices. However, the findings highlight social vulnerabilities and the need for improved access to healthcare. Enhancing reproductive health services in Brazil remains essential to reduce vertical transmission and ensure comprehensive care.
References
Batista, C. J. B., Correa, R. G., Evangelista, L. R., Fleck, K., Silva, L., Renaud, F., Vitoria, M., et al. (2019). The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. Medicine (Baltimore) 8(10):e14828. https://doi.org/10.1097/MD.0000000000014828
Beck, S. T., Cauzzo, L. D. C., Vielmo, L. & Andrade, C. S. (2018). Perfil de gestantes em tratamento para a infecção pelo vírus da imunodeficiência humana. Rev Epidemiol Controle Infec. 8(3), 210-215. https://doi.org/10.17058/reci.v8i3.11190
Brasil (2015). Portaria Ministério da Saúde n 65, de 9 de novembro de 2015. Brasília: Diário Oficial da União Federativa do Brasil; Ministério da Saúde.
Brasil (2019). Relatório de monitoramento clínico das gestantes vivendo com HIV 2019. Brasília: Ministério da Saúde.
Brasil (2022). Boletim Epidemiológico HIV / Aids | 2022. Brasília: Ministério da Saúde.
Campany, L. N. D. S., Amaral, D. M., & Santos, R. (2021). HIV/aids no Brasil: feminização da epidemia em análise. Revista Bioética. 29(1), 374-383. https://doi.org/10.1590/1983-80422021292475
Castelo Filho, A. (2001). Recomendações para terapia antirretroviral em adultos e adolescentes infectados pelo HIV. In: Castelo Filho, A. (Org.). Recomendações para terapia antirretroviral em adultos e adolescentes infectados pelo HIV. São Paulo: Escola Paulista de Medicina; p. 31-31.
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., et al. (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 331(18), 1173-80. https://doi.org/10.1056/NEJM199411033311801.
Domingues, R. M., Szwarcwald, C. L., Souza, P. R. Jr., & Leal, M.do C. (2015) Prenatal testing and prevalence of HIV infection during pregnancy: data from the "Birth in Brazil" study, a national hospital-based study. BMC Infect Dis.15(1), e100. https://doi.org/10.1186/s12879-015-0837-8
Domingues, R. M. S. M., Saraceni, V., & Leal, M. D. C. (2018) Mother to child transmission of HIV in Brazil: Data from the "Birth in Brazil study", a national hospital-based study. PLoS One. 8;13(2), e0192985. https://doi.org/10.1371/journal.pone.0192985
El Beitune, P., Duarte, G., Machado, A. A., Quintana, S. M., Figueiró-Filho, E. A., & Abduch, R. (2005) Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates. Clinics. 60(3), 207-212.
https://doi.org/10.1590/S1807-59322005000300005
Ford, N., Calmy, A., Andrieux-Meyer, I., Hargreaves, S., Mills, E. J., & Shubber, Z. (2013) Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS. 27(7), 1135-43. https://doi.org/10.1097/QAD.0b013e32835e0752
IBGE – Instituto Brasileiro de Geografia e Estatística (2021). Projeção da População do Brasil e das Unidades Federativas [Internet]. Brasília: IBGE; [citado 2023 Jul 21]. https://www.ibge.gov.br/cidades-e-estados
Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V., Berger, D. S., et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 5;374(9692), 796-806.https://doi.org/10.1016/S0140-6736(09)60918-1
Maliakkal, A., Walmsley, S., & Tseng, A. (2016) Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy. J Acquir Immune Defic Syndr. 72(2), 153-61. https://doi.org/10.1097/QAI.0000000000000932
Mendes, J. C., Ceccato, M. D. G. B., Reis, A. M. M., Costa, A. M. G. D, Pantuzza, L. L. N., Furtado, S. S., et al. (2023) Active Pharmacovigilance Project on the safety profile of Dolutegravir in Brazil. AIDS Care. 35(5), 729-738. https://doi.org/10.1080/09540121.2022.2062289
Pereira, G. F. M., Kim, A., Jalil, E. M., Fernandes Fonseca, F., Shepherd, B. E., Veloso, V. G., et al. (2021) National Cohort Study of Dolutegravir and Pregnancy Outcomes in Brazil. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 8(1), e33-e41. https://doi.org/10.1016/S2352-3018(20)30268-X
Pereira, G. F. M., Sabidó, M., Caruso, A., Oliveira, S. B. D., Mesquita, F., & Benzaken, A. S. (2016) Prevalência de HIV em grávidas brasileiras: pesquisa nacional. Rev Bras Ginecol Obstet. 38, 391-398. https://doi.org/10.1055/s-0036-1592102
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. Scientific research methodology. Editora UAB/NTE/UFSM.
Santos, S. F. (2018) Adesão a terapia com efavirenz, tenofovir e lamivudina antes e após a alteração pelo regime em dose fixa combinada [dissertação]. Belo Horizonte: Universidade Federal de Minas Gerais; 104 p.
Senise, J., Cruz. R., Palacios, R., Bonafé, S., Vaz, M. J. R., Lacerda, A.P., et al. (2008) Low-birth weight and pre-term delivery in relation to lopinavir/ritonavir use in pregnancy. Am J Infect Dis. 4(4), 209-214. https://doi.org/10.3844/ajidsp.2008.209.214
Shitsuka, R. et al. (2014). Matemática fundamental para tecnologia. (2a ed.). Editora Erica.
Toassi, R. F. C. & Petry, P. C. (2021). Metodologia científica aplicada a área da saúde. (2a ed.). Editora da UFRGS.
Vrouenraets, S. M., Wit, F. W., Van Tongeren, J., & Lange, J. M. (2007) Efavirenz: a review. Expert Opin Pharmacother. 8(6), 851-871. https://doi.org/10.1517/14656566.8.6.851
WHO - World Health Organization (2018). Potential safety issue affecting women living with HIV using dolutegravir at the time of conception [Internet]. Geneva: WHO; [citado 2023 Jul 21]. https://www.who.int/hiv/mediacentre/news/dtg-statement/en/
WHO - World Health Organization (2019). Update of recommendations on first- and second-line antiretroviral regimens. Geneva: World Health Organization. https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Solange Cristina Teixeira de Lima; Maria das Graças Braga ; Jullye Campos Mendes; Matheus Marchesotti Dutra Ferraz; Pedro Olmo Stancioli Vaz de Melo; Micheline Rosa Silveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
